Mei pharma reports third quarter fiscal year 2025 cash position

San diego--(business wire)--mei pharma, inc. (nasdaq: meip) (the “company”) today reported results for its third quarter ended march 31, 2025. as previously announced in july 2024, the company is continuing its review and evaluation of potential strategic alternatives. as part of this assessment, the company is considering options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockh.
MEI Ratings Summary
MEI Quant Ranking